Stent coating method

• US 20040180131A1
• Filed: 03/14/2003
• Published: 09/16/2004
• Est. Priority Date: 03/14/2003
• Status: Abandoned Application

• Current Assignee: Medtronic Ave
• Original Assignee: Medtronic Ave
• Inventors: Cheng, Peiwen
• Application Number:
  US10/389,084
• Publication Number:
  US 20040180131A1
• Time in Patent Office: Days
• US Class Current: 427/2.24
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2420/02 Methods for coating medical devices
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 33/10 Homopolymers or copolymers of methacrylic acid esters
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

Methods for coating a stent according to the invention include mixing a plurality of compounds to form a solution and applying the solution to a stent frame. The solution is dried on the stent frame to substantially evaporate solvent(s). In one embodiment, the solution includes at least one therapeutic agent, a poly(□-caprolactone) polymer, and a tetrahydrofurane solvent. In another embodiment, the solution includes a Resten-NG therapeutic agent, at least one polymer, and at least one solvent including methanol. In yet another embodiment, the solution includes a podophyllotoxin therapeutic agent, at least one poly(n-butylmethacrylate-co-vinylacetate) polymer, and at least one solvent.

Claims

1. A method for coating a stent, comprising:

mixing at least one therapeutic agent, a poly(□

-caprolactone) polymer, and a tetrahydrofurane solvent to form a solution;

applying the solution to a stent frame; and

drying the solution on the stent frame to substantially evaporate the solvent.

2. The method of claim 1 wherein the therapeutic agent is selected from a group consisting of etoposide, sulindac, and tranilast.

3. The method of claim 1 wherein the solution has a weight-to-weight ratio of therapeutic agent and polymer to solvent of about one percent.

4. The method of claim 1 wherein the solution is applied by spray coating.

5. The method of claim 1 wherein the solution is applied by dipping.

6. The method of claim 1 further comprising applying a cap coating to the stent frame.

7. A method for coating a stent, comprising:

mixing a Resten-NG therapeutic agent, at least one polymer, and at least one solvent including methanol to form a solution;

applying the solution to a stent frame; and

drying the solution on the stent frame to substantially evaporate the solvent.

8. The method of claim 7 wherein the polymer is selected from a group consisting of poly(□

-caprolactone), poly(ethylene-co-vinylacetate), poly(hydroxyl-alkylmethacrylate), and poly(n-vinylpyrrolidone).

9. The method of claim 7 wherein the solvent is selected from a group consisting of chloroform and water.

10. The method of claim 7 wherein the solution is applied by spray coating.

11. The method of claim 7 wherein the solution is applied by dipping.

12. The method of claim 7 further comprising applying a cap coating to the stent frame.

13. The method of claim 12 wherein applying the cap coating comprises:

mixing a poly(n-butylmethacrylate-co-vinylacetate) polymer and a acetone solvent to form a cap solution;

applying the cap solution to the coated stent frame; and

drying the cap solution on the coated stent frame to substantially evaporate the acetone solvent.

14. A method for coating a stent, comprising:

mixing a podophyllotoxin therapeutic agent, at least one poly(n-butylmethacrylate-co-vinylacetate) polymer, and at least one solvent to form a solution;

applying the solution to a stent frame; and

drying the solution on the stent frame to substantially evaporate the solvent.

15. The method of claim 14 wherein the solvent is selected from a group consisting of tetrahydrofurane and acetone.

16. The method of claim 14 wherein the solution is applied by spray coating.

17. The method of claim 14 wherein the solution is applied by dipping.

18. The method of claim 14 further comprising applying a cap coating to the stent frame.

19. The method of claim 18 wherein applying the cap coating comprises:

mixing poly(n-butylmethacrylate-co-vinylacetate) polymer and a cap solvent to form a cap solution;

applying the cap solution to the coated stent frame; and

drying the cap solution on the coated stent frame to substantially evaporate the cap solvent.

20. The method of claim 19 wherein the cap solvent is selected from a group consisting of tetrahydrofurane and acetone.

21. The method of claim 19 wherein the cap solution includes a podophyllotoxin therapeutic agent.